GUCY2D — guanylate cyclase 2D, retinal

The GUCY2D gene provides essential instructions for making a protein called retinal guanylyl cyclase 1 (RetGC1). This protein is found in the retina, the light-sensitive tissue at the back of the eye, specifically within the specialized cells that detect light, known as rods and cones. When light enters the eye, it triggers a chemical reaction in these cells that sends a visual signal to the brain. After this signal is sent, the cells need to reset themselves so they can detect light again. The RetGC1 protein acts like a reset button, producing a molecule that helps the rods and cones return to their resting state, ready for the next flash of light. When there is a mutation in the GUCY2D gene, this reset process is disrupted. If a person inherits two mutated copies of the gene (one from each parent), the protein may not work at all. This causes a severe condition called Leber congenital amaurosis (LCA), where the light-detecting cells cannot reset, leading to severe vision loss or blindness starting at birth or early infancy. This is an autosomal recessive condition, meaning both parents are usually unaffected carriers. Alternatively, if a person inherits just one specific type of mutated copy of the gene, it can cause the protein to become overactive in the wrong way. This leads to a condition called cone-rod dystrophy, which is an autosomal dominant condition (meaning it can be passed directly from an affected parent to a child). In this condition, the light-detecting cells slowly deteriorate over time, causing a gradual loss of visual sharpness, color vision, and increased sensitivity to light, usually starting in childhood or early adulthood. Understanding which specific mutation a patient has is crucial for predicting how their vision will be affected and for determining if they might benefit from new treatments being developed.

Gene description: Encodes a retinal guanylate cyclase responsible for synthesizing cGMP in photoreceptors, vital for phototransduction and maintaining retinal health.

Patient and family guide: The GUCY2D gene provides essential instructions for making a protein called retinal guanylyl cyclase 1 (RetGC1). This protein is found in the retina, the light-sensitive tissue at the back of the eye, specifically within the specialized cells that detect light, known as rods and cones. When light enters the eye, it triggers a chemical reaction in these cells that sends a visual signal to the brain. After this signal is sent, the cells need to reset themselves so they can detect light again. The RetGC1 protein acts like a reset button, producing a molecule that helps the rods and cones return to their resting state, ready for the next flash of light. When there is a mutation in the GUCY2D gene, this reset process is disrupted. If a person inherits two mutated copies of the gene (one from each parent), the protein may not work at all. This causes a severe condition called Leber congenital amaurosis (LCA), where the light-detecting cells cannot reset, leading to severe vision loss or blindness starting at birth or early infancy. This is an autosomal recessive condition, meaning both parents are usually unaffected carriers. Alternatively, if a person inherits just one specific type of mutated copy of the gene, it can cause the protein to become overactive in the wrong way. This leads to a condition called cone-rod dystrophy, which is an autosomal dominant condition (meaning it can be passed directly from an affected parent to a child). In this condition, the light-detecting cells slowly deteriorate over time, causing a gradual loss of visual sharpness, color vision, and increased sensitivity to light, usually starting in childhood or early adulthood. Understanding which specific mutation a patient has is crucial for predicting how their vision will be affected and for determining if they might benefit from new treatments being developed.

Gene function: GUCY2D encodes Retinal Guanylate Cyclase-1 (RetGC1), a key enzyme in the phototransduction cascade. RetGC1 catalyzes the synthesis of cGMP from GTP in photoreceptor outer segments. This cGMP opens cGMP-gated ion channels, leading to depolarization in the dark. Upon light stimulation, cGMP levels decrease, closing these channels and hyperpolarizing the cell, initiating the visual signal. Proper RetGC1 function is critical for photoreceptor viability and visual cycle regulation.

Protein structure: The GUCY2D gene encodes retinal guanylyl cyclase 1 (RetGC1), a membrane-bound protein consisting of 1,103 amino acids. The protein structure is characterized by several distinct domains typical of membrane guanylyl cyclases. It features a hydrophobic amino-terminal signal sequence, a large extracellular domain, a single transmembrane spanning segment, an intracellular kinase homology domain (KHD), a dimerization domain, and a C-terminal guanylyl cyclase catalytic domain. RetGC1 functions as a homodimer, meaning two identical protein molecules assemble together to form the active enzyme. The dimerization domain, which forms a coiled-coil structure, is crucial for this assembly and is the site of the mutation hotspot (codon 838) associated with autosomal dominant cone-rod dystrophy. The intracellular portion of the protein also contains calcium-regulated modules that interact with guanylate cyclase-activating proteins (GCAPs), which are essential for regulating the enzyme's catalytic activity in response to changes in intracellular calcium levels during phototransduction.

Molecular function: The GUCY2D gene encodes retinal guanylyl cyclase 1 (RetGC1), a membrane-bound enzyme that is a critical component of the phototransduction cascade in rod and cone photoreceptors. The primary molecular function of RetGC1 is to catalyze the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). In the dark, high levels of cGMP keep cyclic nucleotide-gated (CNG) ion channels open, maintaining the photoreceptor in a depolarized state. When light strikes the photoreceptor, it activates a signaling cascade that rapidly degrades cGMP, causing the CNG channels to close and the cell to hyperpolarize, which generates the visual signal. This hyperpolarization also leads to a decrease in intracellular calcium concentration. The drop in calcium activates guanylate cyclase-activating proteins (GCAPs), which in turn stimulate RetGC1 to synthesize new cGMP. The restoration of cGMP levels reopens the CNG channels, returning the photoreceptor to its dark-adapted, resting state, ready to respond to the next light stimulus. Therefore, RetGC1 is essential for the recovery phase of phototransduction. Without functional RetGC1, photoreceptors cannot replenish cGMP, leaving them in a persistent state of light adaptation and unable to transmit further visual signals, which is the biochemical basis for the severe vision loss seen in GUCY2D-related diseases.

Expression pattern: The GUCY2D gene is primarily expressed in the retina, specifically within the outer segments of both rod and cone photoreceptor cells. Its expression is critical for the normal function of these light-detecting cells. The encoded protein, retinal guanylyl cyclase 1 (RetGC1), is localized to the intracellular membrane of the photoreceptor outer segments, where it plays a central role in the phototransduction cascade. While the highest levels of expression are found in the retina, some studies have noted low levels of expression in other tissues, though the primary physiological role and disease associations are strictly confined to retinal function. The specific localization within the photoreceptor outer segments ensures that the enzyme is perfectly positioned to interact with guanylate cyclase-activating proteins (GCAPs) and rapidly restore cyclic GMP levels following light exposure.

Mutation spectrum: The mutation spectrum of the GUCY2D gene includes a wide variety of genetic alterations, such as missense, nonsense, frameshift, and splice-site mutations. Biallelic mutations, which are typically loss-of-function variants distributed throughout the gene, are responsible for Leber congenital amaurosis (LCA1). These mutations account for approximately 10-20% of all LCA cases. In contrast, mutations causing autosomal dominant cone-rod dystrophy (CORD6) are almost exclusively missense mutations that cluster in a specific hotspot region at codon 838 within exon 13. This codon is located in the dimerization domain of the protein, and mutations here alter the enzyme's sensitivity to calcium rather than destroying its catalytic activity. Over 100 pathogenic variants have been identified in the GUCY2D gene, reflecting its significant role in inherited retinal diseases.

Pathogenic variants: 1. p.Arg838Cys (c.2512C>T) - A common missense mutation at the codon 838 hotspot, associated with autosomal dominant cone-rod dystrophy (CORD6). It alters the calcium sensitivity of the enzyme, leading to progressive photoreceptor degeneration. 2. p.Arg838His (c.2513G>A) - Another frequent missense mutation at the same hotspot, also causing CORD6 with a similar mechanism of altered calcium sensitivity and progressive vision loss. 3. p.Glu837Asp/p.Arg838Ser - A complex allele involving two adjacent mutations, associated with a more severe phenotype of autosomal dominant cone-rod dystrophy. 4. p.Phe565Serfs*5 - A frameshift mutation that leads to a premature stop codon and a truncated, nonfunctional protein. This type of null mutation is typically associated with autosomal recessive Leber congenital amaurosis (LCA1). 5. p.Arg768Trp - A missense mutation that impairs the catalytic activity of the enzyme, contributing to the severe congenital visual impairment seen in LCA1 when present in a biallelic state.

Clinical significance: Mutations in the GUCY2D gene manifest clinically in two primary forms of inherited retinal disease: Leber congenital amaurosis type 1 (LCA1) and cone-rod dystrophy 6 (CORD6). LCA1 is an autosomal recessive condition characterized by severe visual impairment beginning at birth or shortly thereafter. Patients typically present with poor visual acuity (often hand motion to no light perception), nystagmus, photophobia, and a relatively unremarkable fundus appearance initially, though older patients may develop peripheral and macular degeneration. Despite the profound functional deficit, optical coherence tomography (OCT) often reveals relatively preserved photoreceptor structure, particularly in the fovea. Conversely, CORD6 is an autosomal dominant condition that typically presents later in life, often in the first or second decade. It is characterized by a progressive loss of visual acuity, photophobia, and impaired color vision. As the disease advances, patients experience progressive macular alterations ranging from retinal pigment epithelium mottling to profound central chorioretinal atrophy. Unlike LCA1, CORD6 involves progressive outer retinal thinning and structural deterioration over time. Rare cases of autosomal recessive cone-rod dystrophy and congenital stationary night blindness have also been associated with GUCY2D mutations.

Inheritance: Autosomal Dominant

Chromosomal location: 17p13.1

Genotype-phenotype correlations: There is a strong genotype-phenotype correlation associated with GUCY2D mutations, primarily driven by the functional consequences of the specific genetic alterations. Biallelic null mutations, which lead to a severely truncated or completely nonfunctional RetGC1 protein, result in the severe, early-onset phenotype of Leber congenital amaurosis (LCA1). In these cases, the inability to synthesize cGMP prevents photoreceptors from recovering from light exposure, leading to profound congenital blindness despite initially preserved retinal structure. In contrast, missense mutations that cause autosomal dominant cone-rod dystrophy (CORD6) typically cluster at codon 838 in the dimerization domain of the protein. These mutations do not abolish enzyme activity; rather, they alter the calcium sensitivity of the RetGC1-GCAP complex. This shift results in excessive cGMP production and a persistent influx of calcium ions into the photoreceptors, triggering progressive cellular toxicity and degeneration. Thus, the specific location and functional impact of the mutation dictate whether the patient will experience congenital blindness (LCA1) or progressive retinal degeneration (CORD6).

Research and therapeutic approaches: Currently, there are no FDA-approved therapies specifically for GUCY2D-related inherited retinal diseases, unlike the approved gene therapy Luxturna (voretigene neparvovec-rzyl) which is exclusively for RPE65 mutations. However, significant progress is being made in the development of targeted gene therapies, particularly for Leber congenital amaurosis type 1 (LCA1), because the retinal structure in these patients often remains relatively intact despite severe vision loss, providing a viable target for gene augmentation. The most advanced therapeutic candidate is ATSN-101 (formerly SAR439483), an AAV5-based gene therapy developed by Atsena Therapeutics. This therapy delivers a functional copy of the human GUCY2D gene directly to the photoreceptors via subretinal injection. A Phase 1/2 clinical trial (NCT03920007) evaluating the safety and efficacy of ATSN-101 in patients with biallelic GUCY2D mutations has shown promising results. Data published in The Lancet demonstrated that the therapy was well-tolerated and resulted in clinically meaningful improvements in visual function, including increased retinal sensitivity and improved performance on mobility tests, particularly at the highest dose level. Based on these positive outcomes, ATSN-101 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, and plans for a pivotal Phase 3 trial are underway. Research into treatments for the dominant CORD6 phenotype is also ongoing, though it presents a different challenge as it requires silencing the mutant allele or correcting the specific mutation rather than simple gene augmentation.

Diagnostic testing: Mutations in the GUCY2D gene are typically detected through comprehensive genetic testing approaches, including targeted retinal gene panels, whole exome sequencing, and whole genome sequencing. These methods can identify sequence variants and copy number variations with high sensitivity. Clinical evaluation often involves full-field and pattern electroretinography (ERG), fundus autofluorescence (FAF), and optical coherence tomography (OCT) to assess functional and structural retinal changes. Genetic counseling is a critical component of the diagnostic process. For LCA1, which is inherited in an autosomal recessive manner, parents of an affected individual are obligate carriers, and there is a 25% chance with each pregnancy of having another affected child. For CORD6, which is autosomal dominant, an affected individual has a 50% chance of passing the mutated gene to each offspring. Identifying the specific mutation is essential not only for confirming the diagnosis and inheritance pattern but also for determining eligibility for emerging gene therapies.

Animal models: The primary animal models used to study GUCY2D-related inherited retinal diseases include mouse and zebrafish models. The RetGC1/RetGC2 double knockout (GCdko) mouse model, which lacks both rod and cone function, has been instrumental in demonstrating that AAV-mediated gene therapy can restore visual function and preserve photoreceptor structure. Another model, the cpfl9 mouse, exhibits a milder cone degenerative disease compared to other models of GUCY2D deficiency. In zebrafish, knockdown of the orthologous Gucy2f gene results in early visual dysfunction and photoreceptor layer dystrophy, including the loss and shortening of cone and rod outer segments, providing a robust model for studying LCA1 mechanisms and potential therapies.

Population genetics: The population genetics of GUCY2D mutations reveal specific patterns depending on the phenotype. For Leber congenital amaurosis (LCA1), which is inherited in an autosomal recessive manner, the carrier frequency in the general population is relatively low, but it is a leading cause of LCA, accounting for up to 20% of cases. Certain populations exhibit founder effects, where a specific mutation is unusually prevalent due to descent from a small ancestral group. For example, the c.2943delG mutation has been identified as a founder mutation in pedigrees of Finnish origin. For autosomal dominant cone-rod dystrophy (CORD6), mutations at the codon 838 hotspot are the most common cause, accounting for approximately 35% of autosomal dominant cone-rod dystrophy cases. These mutations have been observed across diverse ethnic groups, suggesting that codon 838 is a highly mutable site rather than the result of a single founder event.

Selected references: 1. Perrault I, et al. Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet, 1996. PMID: 8896569 2. Kelsell RE, et al. Localisation of a gene for dominant cone-rod dystrophy (CORD6) to chromosome 17p. Hum Mol Genet, 1997. PMID: 9097964 3. Sharon D, et al. Genotype-functional-phenotype correlations in photoreceptor guanylate cyclase (GC-E) encoded by GUCY2D. Prog Retin Eye Res, 2018. PMID: 29122701 4. Boye SL, et al. Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis. Mol Ther Methods Clin Dev, 2023. PMID: 37025594 5. Yang P, et al. Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study. Lancet, 2024. PMID: 39255800 6. Stiebel-Kalish H, et al. Gucy2f zebrafish knockdown - a model for Gucy2d-related leber congenital amaurosis. Eur J Hum Genet, 2012. PMID: 22378290 7. Jacobson SG, et al. Safety and improved efficacy signals following gene therapy in childhood blindness caused by GUCY2D mutations. iScience, 2021. PMID: 33997708